Reported Earnings • May 09
First quarter 2026 earnings released: JP¥2.74 loss per share (vs JP¥3.98 loss in 1Q 2025) First quarter 2026 results: JP¥2.74 loss per share (improved from JP¥3.98 loss in 1Q 2025). Revenue: JP¥203.0m (up 20% from 1Q 2025). Net loss: JP¥1.08b (loss narrowed 13% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. 공시 • May 08
AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026 AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026 Board Change • Apr 01
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 1 highly experienced director. CEO, President & Representative Director Ei Yamada is the most experienced director on the board, commencing their role in 2001. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • Mar 26
Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis Patients Vasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population. New Risk • Feb 11
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.9b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥4.9b free cash flow). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change). Reported Earnings • Feb 11
Full year 2025 earnings released: JP¥14.44 loss per share (vs JP¥120 loss in FY 2024) Full year 2025 results: JP¥14.44 loss per share (improved from JP¥120 loss in FY 2024). Revenue: JP¥874.0m (up 36% from FY 2024). Net loss: JP¥5.12b (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. 공시 • Feb 10
AnGes, Inc., Annual General Meeting, Mar 27, 2026 AnGes, Inc., Annual General Meeting, Mar 27, 2026. 공시 • Dec 03
AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026 AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026 Reported Earnings • Nov 09
Third quarter 2025 earnings released: JP¥1.93 loss per share (vs JP¥15.06 loss in 3Q 2024) Third quarter 2025 results: JP¥1.93 loss per share (improved from JP¥15.06 loss in 3Q 2024). Revenue: JP¥232.0m (up 87% from 3Q 2024). Net loss: JP¥722.0m (loss narrowed 80% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. 공시 • Sep 04
Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients A groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population. 공시 • Sep 01
AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025 AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025 Reported Earnings • Aug 10
Second quarter 2025 earnings released: JP¥7.91 loss per share (vs JP¥7.54 loss in 2Q 2024) Second quarter 2025 results: JP¥7.91 loss per share (further deteriorated from JP¥7.54 loss in 2Q 2024). Revenue: JP¥245.0m (up 4.7% from 2Q 2024). Net loss: JP¥2.72b (loss widened 62% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. New Risk • Jul 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥6.7b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥6.7b free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risk Revenue is less than US$5m (JP¥699m revenue, or US$4.7m). 공시 • May 31
AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025 AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025 Reported Earnings • May 10
First quarter 2025 earnings released: JP¥3.98 loss per share (vs JP¥9.14 loss in 1Q 2024) First quarter 2025 results: JP¥3.98 loss per share (improved from JP¥9.14 loss in 1Q 2024). Revenue: JP¥169.0m (up 50% from 1Q 2024). Net loss: JP¥1.25b (loss narrowed 32% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 05
Full year 2024 earnings released: JP¥120 loss per share (vs JP¥39.29 loss in FY 2023) Full year 2024 results: JP¥120 loss per share (further deteriorated from JP¥39.29 loss in FY 2023). Revenue: JP¥643.0m (up 323% from FY 2023). Net loss: JP¥28.1b (loss widened 278% from FY 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. External Independent Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 공시 • Mar 01
AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025 AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025 New Risk • Feb 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥6.7b free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Revenue is less than US$5m (JP¥643m revenue, or US$4.3m). Reported Earnings • Feb 16
Full year 2024 earnings released: JP¥120 loss per share (vs JP¥39.29 loss in FY 2023) Full year 2024 results: JP¥120 loss per share (further deteriorated from JP¥39.29 loss in FY 2023). Revenue: JP¥643.0m (up 323% from FY 2023). Net loss: JP¥28.1b (loss widened 278% from FY 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. 공시 • Feb 14
AnGes, Inc., Annual General Meeting, Mar 28, 2025 AnGes, Inc., Annual General Meeting, Mar 28, 2025. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.9b free cash flow). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (JP¥521m revenue, or US$3.3m). Market cap is less than US$100m (JP¥14.4b market cap, or US$92.2m). 공시 • Dec 03
AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025 AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025 New Risk • Nov 10
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥8.9b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.9b free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Revenue is less than US$5m (JP¥521m revenue, or US$3.4m). Market cap is less than US$100m (JP¥11.8b market cap, or US$77.2m). 공시 • Aug 27
AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024 AnGes, Inc. announced that they will report Q3, 2024 results on Nov 08, 2024 Reported Earnings • Aug 14
Second quarter 2024 earnings released: JP¥7.54 loss per share (vs JP¥10.25 loss in 2Q 2023) Second quarter 2024 results: JP¥7.54 loss per share (improved from JP¥10.25 loss in 2Q 2023). Net loss: JP¥1.68b (loss narrowed 13% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. New Risk • Jul 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.8b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (JP¥249m revenue, or US$1.6m). Market cap is less than US$100m (JP¥11.7b market cap, or US$74.8m). 공시 • Jun 02
AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024 AnGes, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024 Reported Earnings • May 12
First quarter 2024 earnings released: JP¥9.14 loss per share (vs JP¥15.91 loss in 1Q 2023) First quarter 2024 results: JP¥9.14 loss per share (improved from JP¥15.91 loss in 1Q 2023). Net loss: JP¥1.82b (loss narrowed 37% from 1Q 2023). 공시 • Mar 23
AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024 AnGes, Inc. announced that they will report Q1, 2024 results on May 10, 2024 공시 • Mar 20
AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald Europe AnGes, Inc. announced a private placement of 1st unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥1,300,000,000, 2nd unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥32,500,000, and 300,301 stock acquisition rights at a price of ¥53 per stock acquisition right for gross proceeds of ¥15,915,953, for aggregate gross proceeds of ¥1,348,415,953 on March 19, 2024. The transaction for 1st bonds is expected to close on April 5, 2024, 2nd bonds on October 7, 2024, and stock acquisition rights on April 5, 2024. The transaction included participation from new investor Cantor Fitzgerald Europe. New Risk • Feb 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.8b free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (JP¥152m revenue, or US$1.0m). Reported Earnings • Feb 11
Full year 2023 earnings released: JP¥37.17 loss per share (vs JP¥94.29 loss in FY 2022) Full year 2023 results: JP¥37.17 loss per share (improved from JP¥94.29 loss in FY 2022). Net loss: JP¥7.04b (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. 공시 • Feb 11
AnGes, Inc., Annual General Meeting, Mar 28, 2024 AnGes, Inc., Annual General Meeting, Mar 28, 2024. 공시 • Jan 19
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan Eiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL). Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years (p<0.0001) in children and young adults with HGPS. New Risk • Dec 12
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥14.1b (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥10.0b free cash flow). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (JP¥124m revenue, or US$854k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥14.1b market cap, or US$97.2m). 공시 • Dec 05
AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024 AnGes, Inc. announced that they will report fiscal year 2023 results on Feb 09, 2024 공시 • Nov 15
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study Vasomune Therapeutics, Inc. announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study. About AV-001: Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with COVID-19, influenza, bacterial sepsis, acute kidney injury, glaucoma, hemorrhagic shock, sepsis, stroke, and complications associated with diabetes. Importantly, in multiple pre-clinical studies, AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival. Reported Earnings • Nov 09
Third quarter 2023 earnings released: EPS: JP¥0.17 (vs JP¥18.09 loss in 3Q 2022) Third quarter 2023 results: EPS: JP¥0.17 (up from JP¥18.09 loss in 3Q 2022). Net income: JP¥32.0m (up JP¥2.80b from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 59% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 10
Second quarter 2023 earnings released: JP¥10.25 loss per share (vs JP¥29.31 loss in 2Q 2022) Second quarter 2023 results: JP¥10.25 loss per share (improved from JP¥29.31 loss in 2Q 2022). Net loss: JP¥1.92b (loss narrowed 57% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings. 공시 • Jul 13
AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd. On July 12, 2023, AnGes, Inc. closed the transaction. New Risk • Jun 29
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 39% per year over the past 5 years. Revenue is less than US$1m (JP¥68m revenue, or US$472k). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). 공시 • Jun 27
AnGes, Inc. announced that it expects to receive ¥8.481467 million in funding AnGes, Inc. announced a private placement to issue 446,393 43rd stock acquisition right at an issue price of ¥19 per right for the gross proceeds of ¥8,481,467 on June 26, 2023. The transaction will include participation from new investor BofA Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on July 12, 2023. 공시 • May 28
AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023 AnGes, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023 Reported Earnings • May 12
First quarter 2023 earnings released: JP¥15.91 loss per share (vs JP¥19.19 loss in 1Q 2022) First quarter 2023 results: JP¥15.91 loss per share (improved from JP¥19.19 loss in 1Q 2022). Net loss: JP¥2.91b (flat on 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has fallen by 59% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 12
Full year 2022 earnings released: JP¥94.29 loss per share (vs JP¥92.85 loss in FY 2021) Full year 2022 results: JP¥94.29 loss per share (further deteriorated from JP¥92.85 loss in FY 2021). Net loss: JP¥14.7b (loss widened 7.6% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 40% per year. 공시 • Dec 28
AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023 AnGes, Inc. announced that they will report fiscal year 2022 results on Feb 10, 2023 Reported Earnings • Nov 17
Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021) Third quarter 2022 results: JP¥18.09 loss per share (improved from JP¥29.39 loss in 3Q 2021). Net loss: JP¥2.77b (loss narrowed 39% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 40% per year and the company’s share price has also fallen by 40% per year. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 10
Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021) Third quarter 2022 results: JP¥18.09 loss per share (improved from JP¥29.39 loss in 3Q 2021). Net loss: JP¥2.77b (loss narrowed 39% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 40% per year and the company’s share price has also fallen by 40% per year. Reported Earnings • Aug 11
Second quarter 2022 earnings released: JP¥29.31 loss per share (vs JP¥27.72 loss in 2Q 2021) Second quarter 2022 results: JP¥29.31 loss per share (down from JP¥27.72 loss in 2Q 2021). Net loss: JP¥4.49b (loss widened 8.5% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Reported Earnings • May 11
First quarter 2022 earnings released: JP¥19.19 loss per share (vs JP¥24.82 loss in 1Q 2021) First quarter 2022 results: JP¥19.19 loss per share (up from JP¥24.82 loss in 1Q 2021). Net loss: JP¥2.94b (loss narrowed 11% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 12
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥92.85 loss per share (down from JP¥35.32 loss in FY 2020). Net loss: JP¥13.7b (loss widened 225% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 07
Third quarter 2021 earnings released: JP¥29.39 loss per share (vs JP¥10.39 loss in 3Q 2020) Third quarter 2021 results: Net loss: JP¥4.50b (loss widened 252% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Aug 09
Second quarter 2021 earnings released: JP¥27.72 loss per share (vs JP¥8.06 loss in 2Q 2020) Second quarter 2021 results: Net loss: JP¥4.14b (loss widened 323% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Reported Earnings • May 12
First quarter 2021 earnings released: JP¥24.82 loss per share (vs JP¥8.55 loss in 1Q 2020) First quarter 2021 results: Net loss: JP¥3.31b (loss widened 261% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Reported Earnings • Apr 06
Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019) Full year 2020 results: Net loss: JP¥4.21b (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 20
New 90-day low: JP¥1,156 The company is down 18% from its price of JP¥1,406 on 20 November 2020. The Japanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. Reported Earnings • Feb 17
Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019) Full year 2020 results: Net loss: JP¥4.21b (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. 